Reaction
Plasma Cell Myeloma Recurrent reporting signals
As of the last recalculation, Plasma Cell Myeloma Recurrent appears in 3,227 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is BORTEZOMIB (PRR 149.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bortezomib | 1,265 | 149.4 | 151.5 |
| Carfilzomib | 322 | 81.5 | 82.4 |
| Ixazomib | 294 | 72.4 | 73.1 |
| Melphalan | 204 | 61.7 | 62.2 |
| Daratumumab | 340 | 61.2 | 61.8 |
| Thalidomide | 297 | 57.4 | 57.8 |
| Melphalan Hydrochloride | 204 | 56.0 | 56.4 |
| Lenalidomide | 1,693 | 53.3 | 53.5 |
| Dexamethasone 1.5 Mg | 1,353 | 50.6 | 50.8 |
| Dexamethasone | 1,354 | 50.0 | 50.2 |
| Pomalidomide | 513 | 38.1 | 38.3 |
| Selinexor | 41 | 30.9 | 31.1 |
| Acyclovir | 267 | 16.3 | 16.4 |
| Cyclophosphamide Injection, Solution | 335 | 13.5 | 13.5 |
| Cyclophosphamide | 335 | 13.5 | 13.5 |
| Cyclophosphamide For Injection | 335 | 13.5 | 13.5 |
| Filgrastim | 76 | 13.3 | 13.3 |
| Prochlorperazine Maleate | 17 | 12.0 | 12.0 |
| Dexamethasone Sodium Phosphate | 16 | 10.2 | 10.2 |
| Cholestyramine | 17 | 9.1 | 9.1 |
| Valacyclovir | 54 | 8.5 | 8.5 |
| Etoposide | 91 | 8.2 | 8.2 |
| Valacyclovir Hydrochloride | 76 | 7.1 | 7.1 |
| Atovaquone | 8 | 6.4 | 6.4 |
| Bendamustine Hydrochloride | 10 | 5.4 | 5.4 |
| Cisplatin | 64 | 5.4 | 5.4 |
| Daspone | 8 | 5.3 | 5.3 |
| Dapsone Gel, 5% | 8 | 5.3 | 5.3 |
| Zoledronic Acid | 30 | 4.9 | 4.9 |
| Dapsone | 8 | 4.8 | 4.8 |
| Doxorubicin | 65 | 4.8 | 4.8 |
| Sulfamethoxazole And Trimethoprim | 61 | 4.7 | 4.7 |
| Bendamustine Hcl | 11 | 4.6 | 4.6 |
| Doxorubicin Hydrochloride | 22 | 4.4 | 4.4 |
| Venetoclax | 35 | 3.7 | 3.7 |
| Multivitamin | 26 | 3.4 | 3.4 |
| Entecavir | 6 | 3.3 | 3.3 |